Le Lézard
Classified in: Health
Subjects: AWD, NPT, VET

HJF Announces 2024 Heroes of Military Medicine


WASHINGTON, April 29, 2024 /PRNewswire/ -- The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) is pleased to announce the 2024 honorees receiving the HJF Heroes of Military Medicine Awards. 

Since 2010, HJF has celebrated the men, women, and organizations that exemplify the mission of advancing military medicine. The Heroes of Military Medicine Awards dinner will be held on May 9, 2024, at the Washington National Cathedral in Washington, D.C., bringing together top military leaders, medical researchers, practitioners, and thankful citizens to salute those who, through their selfless dedication to military medicine, have improved the lives and health of our Nation's wounded, ill, and injured. 

With the support of generous sponsors, including Chairman Sponsor, Humana Military, the event will recognize exceptional military medical talent benefiting both civilian and military communities nationwide. 

"This year's awardees will be sure to impress you," said Joseph Caravalho, Jr., M.D., HJF President and CEO and retired Army Major General. "Selected by their respective senior service and agency leaders, these honorees exemplify a true commitment to military medicine, having dedicated themselves and their expertise to our nation's warfighters and their families."  

Recipients of the Heroes of Military Medicine Awards will be recognized by a notable lineup of luminaries from Army, Navy, Air Force, and Civilian medicine as well as Keynote speaker, Paul A. Friedrichs, M.D., U.S. Air Force Major General (Ret.).

Jennifer Griffin, the Chief National Security Correspondent for FOX News, will serve as emcee for the twelfth consecutive year.

The 2024 Washington, D.C., Heroes of Military Medicine Award Honorees are: 

About HJF: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) is a global nonprofit organization on a mission to advance military medicine. HJF's scientific, administrative, and program operations services empower investigators, clinicians, and medical researchers around the world to make discoveries in all areas of medicine. With more than 40 years of experience, HJF connects the military medical community, federal and private partners, and the millions of warfighters, veterans, and civilians who benefit from military medicine. For more information, visit hjf.org. 

CONTACT: 
Colleen Franklin
(240) 694-2075
[email protected]

SOURCE Henry M. Jackson Foundation for the Advancement of Military Medicine


These press releases may also interest you

at 08:05
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Viridian Therapeutics, Inc. (the "company" or "Viridian"), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent...

at 08:01
Neuromod Devices Ltd. Appoints Tom Maher as General Counsel
Neuromod Devices Ltd. (Neuromod), the global medical technology business that created the first and only FDA Approved tinnitus treatment device, Lenire, has today announced the appointment of Tom Maher as General Counsel, effective July 5, 2024....

at 08:00
Annual Life Sciences GMP (Good Manufacturing Practices) Master Class 2024 (ON-DEMAND) - ResearchAndMarkets.com
The "Annual GMP Master Class 2024" training has been added to ResearchAndMarkets.com's offering. cGMPs or Current Good Manufacturing Practices is a general encompassing term for the regulations that the control of all facets of life sciences...

at 08:00
The Canadian Dermatology Association Announces 2024 Award Recipients
The Canadian Dermatology Association (CDA) is proud to announce this year's recipients of its Member Awards and Public Education Awards, following a detailed review of nominations received by the Membership and Awards Committee using a thorough...

at 08:00
IntelGenx Obtains Preliminary Efficacy Results for the ?BUENA' Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer's Disease
IntelGenx Corp. (the "Company" or "IntelGenx" a subsidiary of IntelGenx Technologies Corp.) , has successfully completed the BUENA Alzheimer's disease (AD) study. The BUENA study was designed as a Phase 2a proof of concept study to investigate the...

at 08:00
Health Canada Authorizes RYBREVANT® (amivantamab) in Combination with Carboplatin and Pemetrexed as the Only Targeted First-line Treatment Approved for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Johnson & Johnson announced today that Health Canada, through a Priority Review, has issued a Notice of Compliance (NOC) for...

More news about Health...


News published on and distributed by: